Pt(II) Uptake by Dendrimer Outer Pockets: 1. Solventless Ligand Exchange Reaction

Boosting Continuous-Wave Laser-Driven Nonlinear Photothermal White Light Generation by Nanoscale Porosity

The irradiation of an optically absorptive medium by a continuous-wave (CW) near-infrared (NIR) laser can result in a spectral continuum emission covering both the visible and NIR regions, which is attractive for applications as continuum light sources in diverse fields. It is shown here that this NIR-laser-driven light emission can be effectively modulated with nanoscale architecture in the medium. By using porous silica as the model matrix and Yb³⁺ ions as the photothermally active centers, up to 100 folds increment in NIR-laser-induced emission intensity and dramatic decrease in threshold excitation density are demonstrated. It is observed that the emission intensity exhibits a strong nonlinear dependence on the power of the NIR excitation laser, featuring clear excitation power thresholds. Based on combined numerical simulation and spectral and temperature measurements, the improved broadband emission and photothermal nonlinearity are interpreted by enhanced optical energy localization around the laser spot that results in boosting the photon-to-photon conversion efficiency. The use of the nonlinear photothermal emission process as a broadband NIR light source, which could be exploited for applications including NIR spectroscopy, imaging, and sensing, is further demonstrated as a proof-of-concept.

New Strategy for High-Performance Integrated Catalysts for Cracking Hydrocarbon Fuels

In this study, we described the synthesis, characterization, and application of hyperbranched polymer-encapsulated metal nanoparticles (HEMNs) as integrated catalysts for the supercritical cracking of hydrocarbon fuels. The metal precursor was extracted into the organic phase using a hydrocarbon-soluble hyperbranched poly(amidoamine) (CPAMAM) and then reduced in situ by NaBH₄ to produce HEMNs with virtually a single-size distribution. The monitoring of the preparation process by UV-vis demonstrated the feasibility of this encapsulation approach, and the successful synthesis of three different types of HEMNs, metal (Pd, Pt, Au)@CPAMAM, reflected the universality of this method. Compared with the existing catalyst octadecylamine-stabilized Pd nanoparticle, Pd@18N, HEMNs were superior in every aspect. The new encapsulation method allowed metal NPs to have a smaller particle size beneficial to their overall specific surface area and a higher proportion of active surface atoms for a better catalytic activity. Moreover, the space-limiting effect of the polymer allowed the three HEMNs to be highly dispersed in decalin and exhibited admirable stability under storage tests for up to 12 months and high-temperature stability tests at 180 °C. During the supercritical cracking of decalin, Pd@CPAMAM possessed a much better catalytic performance than Pd@18N and CPAMAM (which can also be used as a macroinitiator). To obtain the same heat sink of 3.02 MJ/kg, the temperature could be lowered from 725 to 701, 693, and 699 °C for Pd, Pt, and Au HEMNs, respectively. Pt HEMN turned out to be the best due to its excellent catalytic dehydrogenation/cracking performance, with the conversion of decalin increasing from 22.3 to 50.7% and the heat sink rising from 2.18 to 2.62 MJ/kg with the existence of 50 ppm Pt@CPAMAM, at 675 °C. The significant enhancements were ascribed to the synergistic catalysis through the remarkable abilities of nanometals to catalyze dehydrogenation/cracking of fuel, the supercritical stabilization effects from CPAMAM, and the initiation effects of the hyperbranched polymer CPAMAM.

Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin

Aquated cisplatin was added to half-generation PAMAM dendrimers and the resultant complexes were purified by centrifuge. The drug-dendrimer complexes were then characterised by 1-D and diffusion (1)H NMR and ICP-AES. The amount of drug bound was found to increase in proportion with dendrimer size: G3.5, 22 cis-{Pt(NH(3))(2)} molecules per dendrimer; G4.5, 37; G5.5, 54; and G6.5, 94, which represent only a fraction of the available binding sites on each dendrimer (68, 58, 42 and 37%, respectively). Drug release studies showed that some drug remains bound to the dendrimer even after prolonged incubation with 5'-GMP at temperatures of 60°C for over a week (percentage of drug released 18, 30, 35 and 63%, respectively). Attachment of the drug was found to decrease the radius of the dendrimers. Finally, the effect of the dendrimer on drug cytotoxicity was determined using in vitro assays with the A2780, A2780cis and A2780cp ovarian cancer cell lines. The free dendrimers display no cytotoxicity whilst the drug-dendrimer complexes showed moderate activity. In vivo activity was examined using an A2780 tumour xenograft. Cisplatin, at its maximum tolerated dose of 6 mg/kg, reduced tumour size by 33% compared to an untreated control group. The G6.5 cisplatin-dendrimer complex was administered at two doses (6 and 8 mg/kg equivalent of cisplatin). Both were well tolerated by the mice. The lower dose displayed comparable activity to cisplatin with a tumour volume reduction of 32%, but the higher dose was significantly more active than free cisplatin with a tumour reduction of 45%.